SCHEMBL14224920

SCHEMBL14224920

O=C(c1cc(-c2csc(-c3ccc(O)cc3)n2)c[nH]1)N1CCCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 2/20 0.60
ATP4B P51164 2/20 0.60
POLB P06746 4/20 0.50
ALDH1A1 P00352 3/20 0.50
PKM P14618 3/20 0.50
CDK5 Q00535 3/20 0.50
CDK5R1 Q15078 3/20 0.50
KDM4E B2RXH2 3/20 0.50
MAPT P10636 3/20 0.50
MAPK1 P28482 2/20 0.50
MEN1 O00255 2/20 0.50
LMNA P02545 2/20 0.50
GAA P10253 2/20 0.50
HPGD P15428 2/20 0.50
ALOX12 P18054 2/20 0.50
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
USP2 O75604 1/20 0.50
HSP90AA1 P07900 1/20 0.50
HSP90AB1 P08238 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16404005 0.90 ATP4A (0.59) ATP4AATP4BALDH1A1PKMCDK5
SCHEMBL14224968 0.90 ATP4A (0.59) ATP4AATP4BALDH1A1PKMKDM4E
SCHEMBL16404003 0.90 ATP4A (0.61) ATP4AATP4BPOLBALDH1A1PKM
SCHEMBL14224923 0.90 ATP4A (0.59) ATP4AATP4BALDH1A1PKMCDK5
SCHEMBL14224939 0.90 ATP4A (0.61) ATP4AATP4BPOLBALDH1A1PKM
SCHEMBL16404136 0.88 ATP4A (0.57) ATP4AATP4BPOLBALDH1A1PKM
SCHEMBL14224940 0.87 ATP4A (0.56) ATP4AATP4BPOLBALDH1A1PKM
SCHEMBL14224943 0.87 ATP4A (0.56) ATP4AATP4BALDH1A1PKMCDK5
SCHEMBL16404162 0.86 ATP4A (0.55) ATP4AATP4BPOLBALDH1A1PKM
SCHEMBL14317621 0.86 ATP4A (0.59) ATP4AATP4BALDH1A1PKMCDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2718290-B1 COMPOSITIONS AND METHODS FOR MODULATING A KINASE CLEVEXEL PHARMA (FR) 2016-05-04 EP disclosed
US-8937065-B2 Compositions and methods for modulating a kinase CLEVEXEL PHARMA (FR) 2015-01-20 US disclosed
US-8937065-B2 Compositions and methods for modulating a kinase CLEVEXEL PHARMA (FR) 2015-01-20 US disclosed
WO-2012172438-A9 COMPOSITIONS AND METHODS FOR MODULATING A KINASE DYNAMIX PHARMACEUTICALS LTD. (IL) 2013-02-07 WO disclosed
WO-2012172438-A2 COMPOSITIONS AND METHODS FOR MODULATING A KINASE DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-12-20 WO disclosed
US-20120316148-A1 Compositions and Methods for Modulating a Kinase DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120316148-A1 Compositions and Methods for Modulating a Kinase PRKCH, MAP3K2, MAP3K6 ATP4A 4242/4885ATP4B 4379/4885POLB 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.